© 2023 by The Antibody Society Korea. Proudly created with Wix.com

Oral Session 2   July 5    9:00am - 12:00pm    6 speakers

Chairperson : Hyunbo Shim, Ph.D., Ewha Womans University 

9:00am - 9:25am 

Chimeric Antigen Receptor-Modified T cells: Case Studies

Seung Shin Yu, Ph.D., Helixmith Co., Ltd.

9:25am - 9:50am 

A new CAR-T overcoming the immune suppression

Gunsoo Kim, Curocell Inc.

9:50am - 10:15am 

Universal CAR-NK cell therapy for cancer treatment

Tae-Don Kim, Ph.D., Korea Research Institute of Bioscience and Biotechnology (KRIBB)

10:15am - 10:45am 

Coffee Break & Poster Viewing

10:45am - 11:10am 

Anti-tumor T cell therapy using CTLA4-CD28 gene modification

Kyungho Choi, M.D., Ph.D., Seoul National University

11:10am - 11:35am

US Patent Landscape for Chimeric Antigen Receptor (CAR) T-Cell Therapy and Related Strategy Considerations

Andrew T. Serafini, Ph.D., J.D., Kilpatrick Townsend & Stockton LLP

11:35am - 12:00pm

Novel CAR-T development from AbClon

Kyu-Tae Kim, Ph.D., CSO / Director of BD&L, AbClon Inc.

12:00am - 12:25pm

Development of MVR mAb and CAR T 

Kim, Kwang H., Ph.D., Eutilex